Journal of Cardiothoracic and Vascular Anesthesia
Volume 21, Issue 2 , Pages 179-183 , April 2007

Effects of Hemodilution on Outcome After Modified Blalock-Taussig Shunt Operation in Children With Cyanotic Congenital Heart Disease

References 

  1. Gold JP, Violaris K, Engle MA, et al. A five-year clinical experience with 112 Blalock-Taussig shunts. J Card Surg. 1993;8:9–17
  2. Gladman G, Mc Crindle BW, Williams WG, et al. The modified Blalock-Taussig shunt: Clinical impact and morbidity in Fallot’s tetralogy in the current era. J Thoracic Cardiovasc Surg. 1997;114:25–30
  3. Rao MS, Bhan A, Talwar S, et al. Modified Blalock-Taussig shunt in neonates: Determinants of immediate outcome. Asian Cardiovasc Thorac Ann. 2000;8:339–343
  4. Kirklin JW, Barratt-Boyes BG. Ventricular Septal Defect With Pulmonary Stenosis or Atresia. In: Cardiac Surgery. (ed 3). New York, NY: Churchill Livingstone; 2003;p. 946–1073
  5. Tamisier D, Vouhe PR, Vernant F, et al. Modified BT shunts, results in infants less than 3 months of age. Ann Thorac Surg. 1990;49:797–801
  6. Tsai KT, Chang CH, Lin PJ, et al. Modified BT shunt: Statistical analysis of potential factors influencing shunt outcome. J Cardiovascular Surg. 1996;37:149–152
  7. Al Jubiar KA, Al Jarallah AS, Al Yousuf S, et al. Results of 546 BT shunts performed in 478 patients. Cardiol. 1998;8:486–490
  8. Phornphutkul C, Rosenthal A, Nodas AS, et al. Cerebrovascular accidents in infants and children with cyanotic congenital heart disease. Am J Cardiol. 1973;32:329–334
  9. Grant P, Patel P, Singh S. Acute myocardial infarction secondary to polycythemia in a case of cyanotic congenital heart disease. Int J Cardiol. 1985;9:108–110
  10. Strong WB. Complications of polycythemia in patients who have cyanotic congenital heart disease. Pediatr Rev. 1992;13:379–380
  11. Oldershaw PJ, St John Sutton MG. Hemodynamic effects of hematocrit reduction in patients with polycythemia secondary to CCHD. Br Heart J. 1980;44:584–588
  12. Milam JD, Stephen F, Austin MT, et al. Use of sufficient hemodilution to prevent coagulopathies following surgical correction of cyanotic heart disease. J Thoracic Cardiovasc Surg. 1985;89:623–629
  13. Quaknine-Oriando B, Samama CM, Riou B, et al. Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Anesthesiology. 1999;90:1454–1461
  14. Kohler H, Zschiedrich H, Clasen R, et al. The effects of 500 mL of 10% hydroxyethylstarch 200/0.5 and 10% dextran 40 on blood volume, colloid oncotic pressure and renal function in human volunteers. Anaesthesist. 1982;31:61–67
  15. Treib J, Haass A, Pindur G, et al. All medium starches are not the same: Influence of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrhagic conditions and coagulation. Transfusion. 1996;36:450–455
  16. Tempe DK, Virmani S. Coagulation abnormalities in cyanotic congenital heart disease. J Cardiothorac Vasc Anesth. 2002;16:752–765
  17. Ruttmann TG. Hemodilution enhances coagulation. Br J Anaesth. 2002;88:470–472
  18. Ruttmann TG, James MFM, Aronson I, et al. In vivo investigation into the effects of hemodilution with hydroxyethyl starch (200/0.05) and normal saline on coagulation. Br J Anaesth. 1998;80:612–616
  19. Ruttmann TG, James MFM. Procoagulant effect of in vitro hemodilution is not inhibited by aspirin. Br J Anaesth. 1999;83:350–352
  20. Mortier E, Ongenae M, De Baerdemaeker L, et al. In vitro evaluation of the effect of profound hemodilution with hydroxyethyl starch 6%, modified fluid gelatin 4% and dextran 40 10% on coagulation profile measured by thromboelastography. Anaesthesia. 1997;52:1061–1064
  21. Karoutsos S, Nathan N, Lahrimi A, et al. Thromboelastograph reveals hypercoagulability after administration of gelatin solution. Br J Anaesth. 1999;82:175–177

PII: S1053-0770(06)00058-9

doi: 10.1053/j.jvca.2006.01.029

Journal of Cardiothoracic and Vascular Anesthesia
Volume 21, Issue 2 , Pages 179-183 , April 2007

Article Tools